-
.jpg)
SEER Observational study of 1.3 million cancer patients
Ground-breaking study shows low rates of germline testing in cancer patients especially among Asian, Black, and Hispanic patients.
Learn More -
-
New Genetics in Medicine Publication
demonstrates a 10% lower rate of VUS with WES/WGS compared to panels
Learn More -
Now Available
Expanded Coveragewith up to 91 Genes
Accessible. Affordable. Actionable.
No qualified patient should go without necessary testing due to cost.
4 OUT OF 5 PATIENTS PAY
$0
AVERAGE COST FOR PATIENTS WHO DO PAY
(individual patient responsibility amounts may vary)LESS THAN
$100
STAY INFORMED OF AMBRY UPDATES!
Sign up for our newsletter and be in the know.
Who We Are
With over 20 years of scientific innovations and discoveries, Ambry is an industry leader enabling healthcare professionals to confidently make informed care decisions with their patients by providing them with advanced genetic testing solutions.
At Ambry, people are at the center of our advancements, which starts with our own team. Recognized as an award-winning and outstanding place to work, we maintain a commitment to fostering diverse knowledge and perspectives to drive meaningful collaboration and help us all strive toward better health.